News | March 07, 2025
Biocon Biologics and Civica collaborate to expand Insulin Aspart access in US
There are 38.4 million people with diabetes in the United States
There are 38.4 million people with diabetes in the United States
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Biocon Biologics remains committed to global standards of quality and compliance
Subscribe To Our Newsletter & Stay Updated
